Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort
ABSTRACT Several prospective studies suggest that C-Reactive Protein (CRP), a non-specific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC) whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50yrs-85yrs) in the U.S. National Health and Nutrition Examination Survey III (1988-94), a nationally representative cohort (n=33,994; 2m-85 yrs) with vital status follow-up to 2000. Hazard Ratios (HR) for mortality associated with baseline Clinically-Raised (≥ 1.00 mg/dL) and Intermediate (≥ 0.22 to 0.99 mg/dL) CRP levels were estimated using Cox Proportional Hazards Regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from Other Obesity-Related Cancers (Other-ORC), 1130 from Cardiovascular Disease (CVD). Participants with Clinically-Raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs=2.36 to 2.47) in comparison to persons with undetected levels. HRs were lower for death from Other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81; respectively). Intermediate CRP level was associated with a non-significant 10% to 21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, P=0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for Waist Circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. © 2013 Wiley Periodicals, Inc.
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Present review article highlights various cardiovascular risk prediction biomarkers by incorporating both traditional risk factors to be used as diagnostic markers and recent technologically generated diagnostic and therapeutic markers. This paper explains traditional biomarkers such as lipid profile, glucose, and hormone level and physiological biomarkers based on measurement of levels of important biomolecules such as serum ferritin, triglyceride to HDLp (high density lipoproteins) ratio, lipophorincholesterol ratio, lipid-lipophorin ratio, LDL cholesterol level, HDLp and apolipoprotein levels, lipophorins and LTPs ratio, sphingolipids, Omega-3 Index, and ST2 level. In addition, immunohistochemical, oxidative stress, inflammatory, anatomical, imaging,genetic,and therapeutic biomarkers have been explained in detail with their investigational specifications.Many of these biomarkers,aloneorincombination,canplayimportantroleinpredictionofrisks,its types,and status ofmorbidity.Asemerging risksarefoundtobeaffiliatedwithminorandmicrolevelfactorsanditsdiagnosisatanearlierstagecouldfindCVD,hence,there is an urgent need of new more authentic,appropriate,and reliable diagnostic and therapeutic markers to confirm disease well in time to start the clinical aid to the patients.Present review aims to discuss new emerging biomarkers that could facilitate more authentic and fast diagnosis of CVDs,HF(heart failures),and various lipid abnormalities and disorders in the future.04/2015; 2015,:1-50. DOI:10.1155/2015/971453
- [Show abstract] [Hide abstract]
ABSTRACT: To investigate the impact of HAART-induced HIV suppression on levels of 24 serological biomarkers of inflammation and immune activation. A prospective cohort study. Biomarkers were measured with multiplex assays in centralized laboratories using stored serum samples contributed by 1697 men during 8903 person-visits in the Multicenter AIDS Cohort Study (MACS) from 1984 to 2009. Using generalized gamma models, we compared biomarker values across three groups, adjusting for possible confounders: HIV-uninfected (NEG); HIV-positive, HAART-naive (NAI); and HAART-exposed with HIV RNA suppressed to less than 50 copies/ml plasma (SUP). We also estimated changes in biomarker levels associated with duration of HIV suppression, using splined generalized gamma regression with a knot at 1 year. Most biomarkers were relatively normalized in the SUP group relative to the NAI group; however, 12 biomarkers in the SUP group were distinct (P < 0.002) from NEG values: CXCL10, C-reactive protein (CRP), sCD14, sTNFR2, tumour necrosis factor-alpha (TNF-α), sCD27, sGP130, interleukin (IL)-8, CCL13, BAFF, GM-CSF and IL-12p70. Thirteen biomarkers exhibited significant changes in the first year after viral suppression, but none changed significantly after that time. Biomarkers of inflammation and immune activation moved towards HIV-negative levels within the first year after HAART-induced HIV suppression. Although several markers of T-cell activation returned to levels present in HIV-negative men, residual immune activation, particularly monocyte/macrophage activation, was present. This residual immune activation may represent a therapeutic target to improve the prognosis of HIV-infected individuals receiving HAART.AIDS (London, England) 02/2015; 29(4):463-71. DOI:10.1097/QAD.0000000000000545 · 6.56 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: C-reactive protein (CRP) is involved in a wide range of diseases. It is a powerful marker for inflammatory processes used for diagnostic and monitoring purposes. We aimed to establish reference values as data on the distribution of serum CRP levels in young European children are scarce.International journal of obesity (2005) 09/2014; 38 Suppl 2:S26-31. DOI:10.1038/ijo.2014.132 · 5.39 Impact Factor